ENTRY       D11752                      Drug
NAME        Enoblituzumab (USAN/INN)
FORMULA     C6474H9990N1726O2030S42
EXACT_MASS  145737.9815
MOL_WEIGHT  145827.6686
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASGFTFS SFGMHWVRQA PGKGLEWVAY ISSDSSAIYY
            ADTVKGRFTI SRDNAKNSLY LQMNSLRDED TAVYYCGRGR ENIYYGSRLD YWGQGTTVTV
            SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
            SSGLYSLSSV VTVPSSSLGT QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELV
            GGPSVFLLPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPPEEQ
            YNSTLRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR
            EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP LVLDSDGSFF LYSKLTVDKS
            RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK
            (Light chain)
            DIQLTQSPSF LSASVGDRVT ITCKASQNVD TNVAWYQQKP GKAPKALIYS ASYRYSGVPS
            RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNNYPFTFGQ GTKLEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H149-H205, H225-L214, H231-H'231, H234-H'234, H266-H326, H372-H430, H'22-H'96, H'149-H'205, H'225-L'214, H'266-H'326, H'327-H'430, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  TYPE      Peptide
EFFICACY    Antineoplastic, Anti-CD276 antibody
  TYPE      Monoclonal antibody
COMMENT     Treatment of cancer
TARGET      CD276 [HSA:80381] [KO:K06746]
  PATHWAY   hsa04514(80381)  Cell adhesion molecules
BRITE       Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD276
                 D11752  Enoblituzumab (USAN/INN)
DBLINKS     CAS: 1353485-38-7
            PubChem: 405226618
///
